• Explore /
  • Poster
  • / A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy.

A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy.

Abstract Poster

Authors

null

Mark H. O'Hara

Hospital of the University of Pennsylvania, Philadelphia, PA

Mark H. O'Hara , Max Miller Wattenberg , Ignacio Garrido-Laguna , Eileen Mary O'Reilly , Michael Jay Yellin , Tibor Keler , Michele Anne Gargano , Nick Niles , Jeremy Drees , Nandita Bose , Jose Luis Iglesias , Gregory Lawrence Beatty

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT04834778

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4201)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4201

Abstract #

TPS4201

Poster Bd #

507a

Abstract Disclosures

Similar Posters

First Author: Luis I. Ruffolo

First Author: Eileen Mary O'Reilly

First Author: Daniel H. Johnson

First Author: Martin Gutierrez